Drug dropped over manufacturing issues

With all high-strength diltiazem to be withdrawn from the Australian market, the TGA has implemented a Serious Scarcity Substitution Instrument (SSSI) to support ongoing access to the calcium channel blocker.

To see the whole article please log in.

Tiffany Walker

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

Retype password

Not a member? Sign up here